Semaglutide vs Tirzepatide: A Research Comparison for Canadian Labs

Fast answer for Canadian research searches: tirzepatide is the stronger match when the study needs dual GIP/GLP-1 signalling or the largest head-to-head effect size; semaglutide is the stronger match when the study needs a GLP-1-only reference compound, deeper cardiovascular-outcomes literature, or broader historical comparability. If the next step is sourcing inspection rather than mechanism review, compare current research-use-only documentation for tirzepatide and semaglutide side by side before considering price or vial size.

The question of semaglutide versus tirzepatide is now the most common one Canadian researchers ask when designing a weight-loss or metabolic study with a GLP-1-class compound. A year ago the answer required caveats because the direct head-to-head data in obesity was missing. With the SURMOUNT-5 readout in May 2025 and the four years of accumulated SURPASS-2 literature behind us, the comparison is now one of the best-characterised head-to-head matchups in modern metabolic pharmacology. This guide walks through the comparison section by section: mechanism, trials, pharmacokinetics, side effects, cardiovascular data, the Canadian market, real-world evidence, sourcing in the research channel, and practical selection criteria for different research contexts.

Northern Compound is editorially independent. Nothing here is medical advice. Any commercial links are for research-use-only source inspection, not personal-use guidance. The purpose is a clear research-grade reference that holds up when the comparison actually matters.

Quick research-use decision path#

If you landed here comparing semaglutide vs tirzepatide, tirzepatide vs semaglutide, Ozempic vs Mounjaro, or Wegovy vs Zepbound, start with the research question rather than the brand name. Tirzepatide is the cleaner fit for dual GIP-plus-GLP-1 study designs and effect-size comparisons. Semaglutide is the cleaner fit for GLP-1-only mechanism work, cardiovascular-evidence comparisons, and protocols that need the deepest reference literature. If the comparison might expand beyond these two rows, open the GLP-1 research compound comparison matrix first so Retatrutide, Cagrilintide, and non-incretin metabolic materials are not collapsed into the wrong mechanism lane; its scored rubric and downloadable CSV worksheet are the better internal link when a reader needs to justify why this should stay a two-compound comparison.

For broader Canadian sourcing context, pair this comparison with the research peptides Canada buyer's guide, the semaglutide Canada guide, and the tirzepatide Canada guide. If the next step is supplier-screening rather than mechanism comparison, use the focused research-sourcing paths for where to buy semaglutide in Canada and where to buy tirzepatide in Canada, or use the broader GLP-1 peptide buyer's checklist for Canadian research materials when the file may expand to Retatrutide, Cagrilintide, or non-incretin metabolic materials. Then compare current research-only listings for semaglutide and tirzepatide. Any commercial research-supply link on this page is for research-use-only sourcing context; verify current batch-level COAs before making supplier decisions.

Current supplier-screening shortcut for Canadian researchers#

If you already know the mechanism difference and are deciding what to verify next, use this shortcut before leaving the page:

• For a GLP-1-only reference compound, inspect the current semaglutide research listing, then cross-check lot-specific COA, identity confirmation, fill amount, storage guidance, and research-use-only labelling.
• For a dual GIP/GLP-1 comparison arm, inspect the current tirzepatide research listing, then apply the same batch-documentation check because supplier histories are generally newer than semaglutide.
• If the study question is broader weight-management signalling rather than a direct two-arm comparison, use the GLP-1 research compound comparison matrix to decide whether retatrutide, cagrilintide, or the best peptides for weight-loss research in Canada should be opened as adjacent research maps.

This shortcut is not a recommendation for personal use. It is a faster research-use-only path from comparison intent to documentation review.

Fresh comparison path for 2026 searches#

Recent Northern Compound traffic to this page is concentrated in short comparison queries, so the fastest path is now split by intent:

• If the query is "semaglutide vs tirzepatide", read the mechanism and head-to-head trial sections below, then inspect semaglutide and tirzepatide only as research-use-only reference materials with current batch COAs.
• If the query is "tirzepatide vs semaglutide Canada", open the tirzepatide Canada guide and semaglutide Canada guide after this comparison so supplier screening stays separate from mechanism claims.
• If the query is "Ozempic vs Mounjaro" or "Wegovy vs Zepbound", treat the brand-name language as regulated-drug context. Northern Compound does not give medical advice, dosing guidance, switching instructions, or personal-use recommendations.

For qualified research-sourcing readers, the commercial path should still be COA-first: product identity, lot recency, purity documentation, and research-use-only labelling before price, vial size, or availability.

If you are comparing Canadian research listings#

For the current search pattern on this page, the practical question is often not only "which mechanism is stronger?" It is "which research-use-only listing is easier to verify today?" Before comparing price or vial size, open both current listings and check the same documentation points side by side:

• Semaglutide: stronger literature depth and longer supplier history, so look for recent batch COA continuity rather than relying on brand familiarity.
• Tirzepatide: stronger dual-incretin effect-size data, so put extra weight on identity confirmation, batch recency, and clear research-use-only labelling.
• Retatrutide and cagrilintide: useful adjacent comparison compounds when the research question extends beyond GLP-1 versus dual GIP/GLP-1.

If a supplier page does not make batch documentation, product identity, storage expectations, and research-use-only status easy to verify, that is a stronger signal than a small price difference.

A fast summary before the details#

If a Canadian researcher is choosing between semaglutide and tirzepatide for a study and wants the short version before the long version:

Choose tirzepatide when the research question is about dual incretin agonism specifically, when effect size matters, when comparing to published SURMOUNT data is the target, or when the study design explicitly contrasts GLP-1-only versus GIP-plus-GLP-1 coverage.

Choose semaglutide when the research question is about GLP-1 biology cleanly without GIP confounding, when the study needs to land next to the largest existing literature base, when cardiovascular effects are part of the question (SELECT data exists for semaglutide and the SURPASS-CVOT data is pending), or when an oral formulation is part of the protocol.

Both compounds are otherwise defensible. The choice is rarely binary in the real world. Many research programmes run both in parallel arms.

The mechanistic core of the comparison#

Semaglutide is a GLP-1 receptor agonist and nothing else. Its structure is a modified version of native GLP-1 with a C18 fatty acid side chain that binds serum albumin and extends its half-life to roughly seven days. At the receptor level it binds GLP-1R with high affinity, produces near-maximal cAMP signalling, and drives both G-protein-mediated and beta-arrestin-mediated downstream effects. The downstream effects are the canonical GLP-1 actions: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, hypothalamic satiety, and the suite of cardiovascular and renal effects that unfold over longer exposure.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Its 39-amino-acid sequence began as modified native GIP with rewritten residues that introduced simultaneous GLP-1 receptor affinity. A C20 fatty diacid side chain binds serum albumin and extends its half-life to roughly five days. At the receptor level it binds GIP-R with affinity comparable to native GIP and binds GLP-1R with lower affinity than native GLP-1. In functional cAMP readouts tirzepatide behaves as a full agonist at GIP-R and a biased partial agonist at GLP-1R.

The biased signalling at GLP-1R is the detail most often missed in casual comparisons. Semaglutide is a balanced GLP-1R agonist engaging both cAMP and beta-arrestin recruitment. Tirzepatide is a cAMP-biased GLP-1R partial agonist. Biased agonism at GLP-1R has been hypothesised to reduce receptor internalisation and tachyphylaxis, which may contribute to sustained effect over prolonged dosing. The direct biological consequence of that biased signalling in humans is still an active area of study, but it is consistent with the observation that tirzepatide tolerability at steady state is broadly comparable to semaglutide despite higher receptor engagement on the GIP side.

The GIP side is the bigger mechanistic departure. GIP agonism contributes effects that GLP-1 agonism alone cannot produce: direct adipocyte receptor engagement with adipose-tissue-specific effects on insulin sensitivity and lipid handling, engagement of hindbrain satiety circuits distinct from those engaged by GLP-1, and a restoration of the beta-cell GIP response that appears to normalise when hyperglycaemia is controlled. Whether those effects are additive to GLP-1 effects or synergistic is mechanistically uncertain. The clinical behaviour is consistent with additive or modestly synergistic contributions.

For a clean conceptual picture, think of semaglutide as a full-bore GLP-1 agonist and tirzepatide as a strong GIP agonist with a moderate GLP-1 partial agonist component added on top. That conceptual picture predicts the trial data well.

SURMOUNT-5: the definitive obesity head-to-head#

SURMOUNT-5 was the first and so far only adequately-powered direct head-to-head trial of tirzepatide and semaglutide in obesity. The results, published in May 2025, resolved a question that the field had been debating since SURMOUNT-1 and STEP-1 were run in parallel populations with no common comparator.

The trial enrolled 751 adults with obesity but without diabetes. Participants were randomised to tirzepatide escalated to a maximum tolerated dose up to 15 mg weekly, or to semaglutide escalated to 2.4 mg weekly, the approved obesity dose. The primary endpoint was percentage change in body weight at 72 weeks. The trial was powered for superiority.

The primary endpoint result was 20.2 percent mean weight reduction on tirzepatide versus 13.7 percent on semaglutide, a statistically and clinically significant difference. Tirzepatide was superior on every prespecified secondary endpoint including the proportion of participants reaching 10, 15, 20, and 25 percent weight reduction thresholds. Forty-two percent of participants on tirzepatide reached the 20 percent threshold compared to twenty-one percent on semaglutide. The 25 percent threshold was reached by thirty-one percent of tirzepatide participants and sixteen percent of semaglutide participants.

The safety profile differed in predictable ways. Gastrointestinal events were numerically more common on tirzepatide at the highest dose. Discontinuation rates for adverse events were 6.1 percent on tirzepatide and 5.4 percent on semaglutide. No unexpected safety signals emerged. Serious adverse event rates were similar between the two arms.

The trial did something useful for the field beyond settling the superiority question. It produced a matched-population dataset where every participant received active drug at the maximally tolerated approved obesity dose under identical protocols. Previous cross-trial comparisons between SURMOUNT-1 tirzepatide data and STEP-1 semaglutide data had suffered from population differences, protocol differences, and placebo response differences that limited interpretation. SURMOUNT-5 removed those confounds.

A remaining caveat worth noting. SURMOUNT-5 compared tirzepatide at full dose ladder to semaglutide at approved obesity dose of 2.4 mg. Higher semaglutide doses of 3.0 and even 4.0 mg have been tested in later-generation trials, and the STEP-UP programme reported the 7.2 mg semaglutide dose produces substantially greater weight loss than 2.4 mg. Whether maximally-dosed semaglutide at 7.2 mg, should it reach clinical use, would close the tirzepatide gap is an open question that remains to be tested. For the purposes of a Canadian researcher comparing compounds that are actually available and approved, SURMOUNT-5 is the right reference.

SURPASS-2: the diabetes head-to-head#

SURPASS-2 was the diabetes-population predecessor to SURMOUNT-5. Published in the New England Journal of Medicine in 2021, it randomised 1,879 adults with type 2 diabetes inadequately controlled on metformin to tirzepatide 5, 10, or 15 mg weekly, or to semaglutide 1 mg weekly. The 1 mg semaglutide dose was the approved type 2 diabetes dose at the time, and remains the reference clinical diabetes dose for semaglutide.

The primary endpoint was change in HbA1c at 40 weeks. Tirzepatide was superior to semaglutide at every tested dose. HbA1c reductions were 2.01, 2.24, and 2.30 percent for tirzepatide 5, 10, and 15 mg respectively, versus 1.86 percent for semaglutide 1 mg. Weight loss ran 7.6, 9.3, and 11.2 kg for tirzepatide versus 5.7 kg for semaglutide. Proportions of participants reaching HbA1c under 7.0 percent ranged from 82 to 86 percent on tirzepatide versus 79 percent on semaglutide, a smaller gap than the weight-loss gap.

SURPASS-2 used the approved diabetes dose of semaglutide, not the higher obesity dose. A direct diabetes comparison at semaglutide's maximum diabetes dose of 2.0 mg was never adequately powered in head-to-head work. Whether semaglutide 2.0 mg closes the gap versus tirzepatide 15 mg is another open question. Most reviewers consider the comparison broadly consistent with the SURMOUNT-5 pattern of tirzepatide superiority but with a smaller gap than the 1 mg versus 15 mg comparison.

Responder distribution: why means hide the more interesting story#

Reporting mean weight loss is the convention but it hides the more informative distribution. Both compounds produce a wide range of responder outcomes. Understanding the distribution matters for research design because studies targeting extreme responders need compounds with long tails, and studies targeting mean effect need compounds with tight distributions.

SURMOUNT-1 data on 2,539 tirzepatide participants showed that at 72 weeks on 15 mg weekly, 36.2 percent of participants exceeded 25 percent weight loss. STEP-1 data on 1,306 semaglutide participants showed that at 68 weeks on 2.4 mg weekly, 13.8 percent exceeded 25 percent weight loss. Both distributions include a meaningful non-responder tail: roughly 10 to 15 percent of participants in either compound lost less than 5 percent of baseline weight despite full protocol adherence.

The non-responder phenomenon is one of the more important open questions in the field. Mechanistic reviews have proposed that non-responders may have genetic variation at the incretin receptor, differences in gut hormone baseline, variation in brain reward circuit responsiveness, or simply more aggressive compensatory appetite behaviour that overwhelms the pharmacological signal. A Canadian researcher running a study should anticipate that any cohort will include non-responders, and the study design should account for that.

The fact that tirzepatide has a larger proportion of extreme responders than semaglutide is part of why some researchers preferentially select it for weight-loss studies where demonstrating maximal achievable effect is the primary interest. The fact that semaglutide has a substantially larger real-world sample size with consistent mean response is part of why other researchers select it for studies where generalisability to the largest population base is the priority.

Pharmacokinetics side by side#

Both compounds are designed for once-weekly subcutaneous administration. The mechanical details differ in small ways that matter for study design.

Semaglutide's plasma half-life is approximately seven days. Steady state is reached by roughly the fifth week at any given dose. Time to peak plasma concentration is 24 to 72 hours post-injection. Subcutaneous bioavailability is approximately 89 percent. Pharmacokinetics are not meaningfully affected by mild-to-moderate hepatic or renal impairment. Clearance is dominated by proteolytic degradation rather than renal or hepatic elimination.

Tirzepatide's plasma half-life is approximately five days. Steady state is reached by roughly the fourth week at any given dose. Time to peak is 24 to 72 hours. Subcutaneous bioavailability is approximately 80 percent. Pharmacokinetics are similarly insensitive to mild-to-moderate organ impairment. Clearance similarly dominated by albumin-bound proteolytic degradation.

The two-day half-life difference is small in clinical practice. Both compounds produce reliable steady-state exposure at weekly dosing. The difference becomes relevant in edge cases: a participant who misses a dose of tirzepatide for more than nine days will have dropped below typical steady-state exposure faster than a semaglutide participant, and catch-up dosing may need to resume titration. Similarly, washout periods for switching between compounds need to account for the residual exposure profile.

For oral semaglutide (Rybelsus), the pharmacokinetic profile is meaningfully different. Oral bioavailability is approximately 1 percent due to protease degradation in the stomach. The salcaprozate sodium absorption enhancer allows transient local permeability. Peak plasma concentration occurs within 30 to 60 minutes but absolute exposure is highly sensitive to food and water intake around dosing. Oral semaglutide works clinically but the pharmacokinetic variability is substantially higher than either injectable form. Tirzepatide has no oral formulation.

Side effect comparison#

Both compounds carry nearly identical adverse event profiles dominated by gastrointestinal symptoms.

Nausea is reported by 15 to 25 percent of semaglutide users and 22 to 33 percent of tirzepatide users across the main trials. Vomiting is reported by 5 to 10 percent of semaglutide users and 8 to 15 percent of tirzepatide users. Diarrhoea runs 10 to 15 percent for semaglutide and 17 to 22 percent for tirzepatide. Constipation is similar between the two at 6 to 11 percent.

The pattern is consistent: tirzepatide produces modestly higher GI event rates, concentrated in titration. Both compounds show declining event rates once participants reach steady state on a given dose. Titration schedules are therefore the standard tolerability-management tool for both compounds, with the default escalation of four weeks per step acceptable for most participants and eight-week per step available for participants with persistent symptoms.

Serious adverse events occur at similar low rates. Acute pancreatitis runs under one percent for both compounds and has not consistently differed from placebo. Gallbladder events are numerically elevated with both compounds, consistent with rapid weight loss of any kind. Both compounds carry the class-level boxed warning for thyroid C-cell tumours driven by rodent medullary thyroid C-cell hyperplasia findings, with the usual contraindication in patients with personal or family history of MTC or MEN2.

Hypoglycaemia on monotherapy is rare for both compounds because both engage glucose-dependent insulin secretion. Rates rise meaningfully when combined with sulfonylureas or insulin.

Injection site reactions are mild for both. Severe injection site reactions are rare and not meaningfully different between compounds.

The one area where the side effect profiles diverge more clearly is muscle mass preservation. The available DEXA data from sub-studies of SURPASS and SURMOUNT show that both compounds produce roughly 25 to 40 percent of weight loss as lean tissue, a concerning proportion for any weight loss intervention. Tirzepatide's lean tissue loss has been characterised as modestly less than semaglutide's in some sub-studies, though the differences are small and of uncertain clinical significance. Both compounds benefit from protein-forward nutrition and resistance training co-interventions. This area is under active research.

Cardiovascular: SELECT versus SURPASS-CVOT#

Semaglutide has completed its dedicated cardiovascular outcomes trial. Tirzepatide has not. This asymmetry is the single most important difference in regulatory and clinical evidence between the two compounds and deserves careful attention.

SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, randomising to semaglutide 2.4 mg weekly or placebo. Over a mean follow-up of 40 months, the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke occurred in 6.5 percent of the semaglutide group versus 8.0 percent of the placebo group, a relative risk reduction of 20 percent. Cardiovascular mortality alone showed a trend toward reduction but did not reach statistical significance as a secondary endpoint. The results established that semaglutide produces meaningful cardiovascular benefit in a population without diabetes, extending the case originally built in SUSTAIN-6 for the diabetic population.

SURPASS-CVOT is the tirzepatide equivalent. It enrolled approximately 13,000 participants with type 2 diabetes and established atherosclerotic cardiovascular disease, with dulaglutide as the active comparator rather than placebo. The design makes SURPASS-CVOT a non-inferiority trial against a confirmed CV-beneficial comparator, a higher statistical bar than placebo-controlled outcome work. Interim safety readouts have been reassuring. The primary endpoint is expected to read out in 2025 or 2026. Until it does, the class-level assumption that tirzepatide produces comparable CV benefit is inference rather than direct evidence.

For a Canadian research programme prioritising cardiovascular endpoints, semaglutide has direct evidence. For a programme prioritising metabolic endpoints agnostic to CV outcomes, either compound is defensible. Researchers should plan study design around the compound with the most aligned evidence base.

The Canadian market: brand names, pricing, availability#

In Canada, semaglutide is sold under three brand names. Ozempic is the weekly subcutaneous injection at 0.25, 0.5, 1.0, and 2.0 mg doses, approved for type 2 diabetes since January 2018. Wegovy is the higher-dose weekly injection at 2.4 mg, approved for chronic weight management in adults with obesity or overweight. Rybelsus is the oral daily formulation at 3, 7, and 14 mg, approved for type 2 diabetes. All three are Novo Nordisk products.

Tirzepatide in Canada is sold under two brand names. Mounjaro is the weekly subcutaneous injection at 2.5, 5, 7.5, 10, 12.5, and 15 mg doses, approved for type 2 diabetes since November 2022. Zepbound is the higher-dose weekly injection for chronic weight management, approved in the months following the SURMOUNT readouts. Both are Eli Lilly products.

Pricing is broadly similar between the two at retail. A monthly supply of either compound at the weekly injection dose runs approximately 400 to 600 Canadian dollars at most pharmacies. Oral Rybelsus is somewhat cheaper on a per-month basis but still substantially more expensive than generic diabetes medications. Provincial coverage under drug plans varies by province and by indication. Diabetes coverage is more consistent than obesity coverage. Private insurance coverage varies by plan tier.

Availability has been a real-world constraint. Both Ozempic and Mounjaro experienced periodic supply shortages in Canadian pharmacies during 2023 and 2024 driven by manufacturing capacity lagging demand. The shortage conditions pushed some Canadian patients toward compounded alternatives in the United States or toward the research peptide channel. Manufacturing capacity has expanded substantially since early 2025 and routine supply is now reasonably consistent, though periodic dose-specific shortages still occur.

Cost comparison: branded versus research-grade#

For Canadian researchers, the cost comparison is most meaningfully framed per milligram of active peptide.

Branded semaglutide at retail pharmacy pricing in Canada ranges from approximately 250 Canadian dollars per month for lower doses of Ozempic up to 450 Canadian dollars per month for Wegovy at 2.4 mg. A 2.4 mg weekly supply delivers approximately 10.4 mg of active peptide per month. Per-milligram cost runs 40 to 50 Canadian dollars.

Branded tirzepatide at retail pharmacy pricing in Canada ranges from approximately 400 to 600 Canadian dollars per month. A 15 mg weekly supply delivers approximately 65 mg of active peptide per month. Per-milligram cost runs 7 to 10 Canadian dollars at the highest dose, but substantially more at lower doses where the total peptide per month is reduced.

Research-grade supply prices differ by vial size. A research-grade 10 mg semaglutide vial typically runs 40 to 60 Canadian dollars at Canadian suppliers, giving a per-milligram cost of 4 to 6 Canadian dollars. A research-grade 30 mg tirzepatide vial typically runs 120 to 180 Canadian dollars, also around 4 to 6 Canadian dollars per milligram.

The research-channel per-milligram costs are roughly comparable between the two compounds, at roughly one-fifth to one-tenth of branded cost. This is consistent with the observation that branded peptide pricing is driven by distribution economics rather than by production cost differences between semaglutide and tirzepatide, which are broadly similar to synthesise.

Switching between compounds: what the research shows#

A meaningful subset of Canadian researchers and participants will at some point switch between semaglutide and tirzepatide, either as a research question or as a practical matter driven by availability or tolerability. The switching literature is thin but consistent.

Switching from semaglutide to tirzepatide is generally well tolerated. Published case series and observational cohorts suggest that participants who switch from stable semaglutide to tirzepatide can start tirzepatide at 2.5 mg with rapid titration rather than the full four-week-per-step protocol, because prior GLP-1 exposure produces partial cross-tolerance to incretin-class gastrointestinal effects. Weight loss typically continues after the switch, with the additional signal from tirzepatide driven primarily by the GIP arm engaging a pathway not previously targeted.

Switching from tirzepatide to semaglutide is less well characterised. The modest subset of participants who have switched for availability or cost reasons report variable outcomes. Some maintain weight loss at a lower steady exposure; others regain a meaningful proportion of loss when transitioning to a compound that engages only half of the original receptor coverage.

Researchers running crossover study designs between the two compounds should allow washout periods of four to eight weeks between arms to minimise residual exposure and plan for the asymmetry of switch directions.

Stack research and combinations#

Both compounds have been explored in combination research, with somewhat different combination partners.

Semaglutide has been paired with cagrilintide, a long-acting amylin receptor agonist, in the CagriSema programme. The Phase 3 REDEFINE-1 trial in obesity without diabetes produced 22.7 percent mean weight reduction at 68 weeks, a number competitive with tirzepatide monotherapy at matched durations. Semaglutide plus cagrilintide is an active development programme at Novo Nordisk.

Tirzepatide has been paired with cagrilintide in research settings, though the Phase 3 programme is less mature than CagriSema. The theoretical rationale is the same: amylin adds a complementary satiety pathway without overlapping the incretin system.

Combinations of either compound with AOD-9604, MOTS-c, or growth hormone secretagogues exist in research-community protocols but are not characterised in controlled work.

Researchers designing combination studies should recognise that adding a second variable complicates attribution of observed effects. A well-powered monotherapy arm remains the default for most research questions.

Research sourcing: availability, batch consistency, and what to look for#

For Canadian researchers sourcing either compound in the research channel, practical considerations differ in small but meaningful ways.

Semaglutide is the more established compound in research supply. It has been sold in the research channel since approximately 2019 and has accumulated more supplier-level batch consistency data, more independent third-party testing results, and more published stability data. Most established suppliers have supplied semaglutide for years. The batch-to-batch purity data is well characterised; a researcher checking Janoshik Analytical reports will generally find semaglutide batches at 99 percent HPLC purity with clean mass spec identity confirmation.

Tirzepatide is the newer compound in research supply, with consistent availability since approximately 2022. The supplier base is narrower. Batch consistency data is less mature. Independent third-party testing of tirzepatide batches is available but less ubiquitous than for semaglutide. A Canadian researcher sourcing tirzepatide should budget additional supplier verification effort relative to semaglutide.

Both compounds are supplied as lyophilised powder in rubber-stoppered vials, typically 10 mg or 30 mg for tirzepatide, or 5 mg or 10 mg for semaglutide. Reconstitution protocols are essentially identical between the two, and the guide on how to reconstitute peptides applies to both. Storage stability data for both in bacteriostatic water at 2 to 8 degrees Celsius supports 28-day use after reconstitution.

Supplier evaluation criteria for both compounds are identical: per-batch COA availability, third-party testing presence (Janoshik or equivalent), Canadian domestic fulfilment, payment options consistent with Canadian buyer preferences, operating history of more than twelve months, and customer service willing to answer technical questions. These criteria are covered in more depth in the research peptides Canada buyer's guide.

One difference in the sourcing landscape worth noting. Tirzepatide compounding in the United States during the FDA shortage window of 2023 and 2024 created a secondary supply channel that does not exist for semaglutide in the same scale. Some Canadian buyers have considered importing compounded tirzepatide from US sources. The regulatory position is that importation of a compounded version of an approved drug carries separate issues from the research-use-only framework, and Canadian enforcement attention has been higher on compounded importation than on research-channel domestic supply.

Real-world evidence at scale#

Both compounds now have substantial real-world evidence bases separate from their registration trials. The RWE matters because trial populations are selected for protocol compliance and monitored carefully, while RWE reflects the broader population's actual experience.

Semaglutide RWE is the larger of the two. Observational studies of Ozempic and Wegovy users across multiple health systems have generally confirmed trial-level weight-loss and HbA1c effects, with mean reductions at 12 months running slightly below registration trial numbers because of imperfect adherence. Discontinuation rates in real-world populations run 30 to 50 percent at 12 months, well above trial rates, largely driven by side effects, cost, and loss of motivation once weight loss plateaus. The cardiovascular benefit seen in SELECT has been supported by RWE analyses of large health system databases.

Tirzepatide RWE is growing rapidly but is still immature relative to semaglutide. Published observational analyses of Mounjaro and Zepbound users have confirmed weight-loss effects broadly consistent with SURMOUNT, with somewhat higher real-world response at the top doses. Discontinuation rates are similar to semaglutide at 12 months, with the same dominant drivers of GI intolerability, cost, and plateau frustration.

A Canadian researcher designing a study that needs to integrate into the broader literature will find more RWE infrastructure around semaglutide than tirzepatide. This is a moving target; tirzepatide RWE is catching up quickly.

Renal, hepatic, and special populations#

Both compounds have been studied in patients with chronic kidney disease, hepatic impairment, older age, and various comorbidities. The patterns are broadly similar.

Moderate chronic kidney disease does not meaningfully alter pharmacokinetics of either compound. Severe renal impairment data are limited for both. Neither compound requires dose adjustment in mild-to-moderate renal dysfunction.

Moderate hepatic impairment does not require dose adjustment for either compound. Severe hepatic impairment data are limited and dose adjustment is advised per clinical judgment.

Older adults, defined as age 65 or older, tolerate both compounds with side effect profiles similar to younger populations. Discontinuation rates are modestly higher in older populations, driven primarily by GI events at titration.

Pregnancy is a contraindication for both compounds. Animal data suggest teratogenic potential and pregnancy safety in humans has not been established. Washout periods of at least 8 weeks prior to conception are advised for semaglutide given its longer half-life; 6 weeks for tirzepatide.

Paediatric indications for semaglutide were approved based on the STEP TEENS trial in adolescents with obesity. Tirzepatide paediatric trials are ongoing with no approved indication as of early 2026.

Choosing between the two for specific research contexts#

The right compound for a given research programme depends on the specific question. Some practical selection heuristics:

For studies primarily interested in weight-loss effect size, tirzepatide is the default choice. SURMOUNT-5 settled the superiority question at matched dose. If the study question is whether any GLP-1-class compound can achieve 20 percent weight loss in a population, tirzepatide is the answer.

For studies investigating GLP-1 receptor biology cleanly, semaglutide is the default choice. Its mono-receptor coverage avoids the confound of GIP agonism that tirzepatide introduces. Semaglutide's deeper literature base also supports cross-comparison with older GLP-1 mono agonist work.

For studies focused on cardiovascular endpoints, semaglutide is the default choice until SURPASS-CVOT reads out. The SELECT data supports inclusion of semaglutide in CV-focused research.

For studies exploring dual incretin biology, tirzepatide is obviously the only choice among approved compounds. Studies investigating GIP-specific effects, adipose tissue remodelling, or the contribution of dual agonism use tirzepatide as the single-compound reference.

For studies that need both injectable and oral formulations, semaglutide is the only option. Rybelsus provides an oral comparator arm in a way that tirzepatide cannot match.

For studies running at matched exposures in crossover or crossed arms, semaglutide's longer half-life and more balanced receptor engagement make it marginally easier to dose-match to prior literature. Tirzepatide's shorter half-life requires more careful washout attention.

For studies prioritising generalisability to the broadest real-world population, semaglutide retains the edge due to its larger RWE base, although this advantage is narrowing as tirzepatide uptake continues.

For studies exploring maximal achievable effect, tirzepatide has the larger extreme-responder tail.

Documentation and handling questions: side by side#

For research-use-only sourcing, the handling comparison should start with documentation, not protocol advice. Canadian researchers comparing semaglutide and tirzepatide should verify the same minimum package before treating either listing as credible: lot-specific COA, third-party identity confirmation, HPLC purity, fill amount, stated storage conditions, expiry or retest date, and research-use-only labelling.

The two compounds are usually supplied as lyophilised material, so supplier pages often discuss storage, cold-chain handling, and bacteriostatic-water compatibility. Treat those details as documentation checkpoints rather than personal-use instructions. If a comparison file depends on bacteriostatic water, sterile water, buffer, pH, preservative exposure, or vehicle-only controls, use the research peptide solvent compatibility matrix before the supplier shortlist becomes a data-quality problem. A credible supplier should make the current batch record easy to inspect before purchase and should not rely on generic, recycled COA screenshots.

Semaglutide has a longer research-channel history, so Canadian researchers can usually find more batch-to-batch documentation examples and independent testing history. Tirzepatide availability has caught up quickly, but newer supplier histories make current-lot verification more important. If the current tirzepatide research listing does not expose clear batch documentation, that is a stronger reason to pause than any small price difference.

For a broader supplier due-diligence path, use the research peptides Canada buyer's guide before comparing live listings for semaglutide and tirzepatide. This page is not medical advice and does not provide administration, reconstitution, or personal-use guidance.

Gaps in the comparison literature#

Despite the substantial data base, three meaningful gaps remain in the comparison literature.

The first is sustained multi-year use beyond 72 weeks. Neither SURMOUNT nor SELECT has carried participants beyond roughly four years. Whether the weight-loss advantages of tirzepatide over semaglutide hold at 5 or 10 year time horizons remains to be characterised. Real-world evidence is beginning to address this question but the cohorts with 3-plus years of continuous tirzepatide use are still small.

The second is the contribution of GIP agonism specifically. The SURMOUNT-5 superiority of tirzepatide over semaglutide is consistent with GIP agonism adding meaningful effect on top of GLP-1 agonism, but a clean mechanistic dissection would require a GIP-only comparator, which does not exist as an approved compound. The hypothesis remains plausible but not directly testable.

The third is head-to-head comparison at the highest clinically-used doses of each compound. SURMOUNT-5 compared tirzepatide 15 mg to semaglutide 2.4 mg, the approved obesity doses at the time. Whether higher semaglutide doses of 3.0 mg or beyond would close the gap is open. STEP-UP has explored 7.2 mg semaglutide and reported it produces substantially greater weight loss than 2.4 mg. A head-to-head at that dose has not been run.

Frequently asked research questions#

Summary for Canadian researchers#

For the core question of semaglutide versus tirzepatide in weight-loss and metabolic research: tirzepatide is superior on mean effect size at matched approved doses in direct head-to-head trials. Semaglutide has the deeper literature base, completed cardiovascular outcomes evidence, the only oral formulation in the class, and broader real-world evidence. For most research programmes either compound is defensible, and the choice should map to the specific research question being asked.

The tirzepatide advantage is clearest in effect-size-focused obesity research. The semaglutide advantage is clearest in cardiovascular-focused research, in mono-receptor mechanism work, and in programmes prioritising generalisability to the broadest existing literature. The two compounds are more complementary than competitive from a research-design perspective; both have meaningful roles in a serious Canadian metabolic research programme.

For practical sourcing considerations, both compounds are widely available from established Canadian research peptide suppliers with per-batch COA availability and third-party testing options. Semaglutide's longer research-channel history produces somewhat more mature batch consistency data. Tirzepatide's rapid expansion since 2022 has closed most of the supplier-infrastructure gap.

The companion pillars on this site cover each compound in depth. Semaglutide in Canada provides the full semaglutide reference. Tirzepatide in Canada provides the tirzepatide equivalent. Retatrutide research guide covers the emerging triple agonist that extends this line of development. Retatrutide vs tirzepatide vs semaglutide includes the three-way comparison.

Trial design considerations when selecting between the two#

A Canadian researcher designing a protocol with either compound has a set of design decisions that differ in practical consequence. The following considerations often determine the compound selection when the underlying research question could be addressed by either.

Power calculation and effect size assumptions. A trial powered on tirzepatide effect size assumptions and then run with semaglutide will be under-powered. A trial powered on semaglutide effect size assumptions and run with tirzepatide will be over-powered but will waste resources. The SURMOUNT-5 data gives the cleanest matched-population estimates for obesity contexts: approximately 20 percent mean weight reduction on tirzepatide and 14 percent on semaglutide at 72 weeks. Power calculations should use these as base rates if the study is targeting similar endpoints.

Washout and crossover design. Tirzepatide's shorter half-life makes it marginally easier to wash out between arms but the difference is small. For crossover designs testing both compounds in the same participants, a washout of four to eight weeks is the conservative standard. Studies aiming to isolate a GIP-specific contribution from a GLP-1-only baseline can use semaglutide as the baseline arm and tirzepatide as the switch arm, avoiding the asymmetry of switching the other direction.

Dose selection and titration schedule. Both compounds use four-week titration steps as the default clinical schedule. Research protocols sometimes use accelerated titration of two-week steps for participants who tolerate dose escalation well, or extended eight-week steps for participants with persistent gastrointestinal symptoms. Selecting a titration schedule that matches the published trial protocols makes results more directly comparable to existing literature. Deviating from standard titration produces results that require additional interpretation.

Outcome measurement cadence. Weekly injectable compounds with five to seven day half-lives reach steady state by the fourth week at any given dose. Primary outcome assessments conducted before week four of a given dose step will under-estimate the dose's steady-state effect. Researchers should anchor primary outcome timing to post-titration windows rather than to calendar time from study initiation.

Participant retention and dropout. Real-world dropout rates of 30 to 50 percent at 12 months apply to both compounds in unselected populations. Research protocols with tight inclusion criteria, careful participant selection, and active adherence support can achieve substantially lower dropout rates, but any study should plan for meaningful attrition. Both compounds benefit from participant education on gastrointestinal symptom management, dose flexibility during titration, and realistic weight-loss expectations.

Biomarker and mechanistic sub-studies. Studies interested in mechanistic dissection benefit from pairing weight and HbA1c outcomes with biomarker sub-studies. For both compounds, useful biomarkers include fasting and postprandial glucose, insulin, C-peptide, GLP-1 and GIP active concentrations (context-dependent given pharmacological exposure of the study drug itself), liver enzymes, lipid panels, and body composition by DEXA. Tirzepatide-specific mechanistic studies often include adipose tissue biopsy or MRI-based body composition to characterise GIP-specific adipose effects. Semaglutide-specific mechanistic studies often include cardiovascular biomarkers given the SELECT evidence base.

Publication and reproducibility. Studies using compounds with larger literature bases produce results that are easier to publish and easier to replicate. Semaglutide has the deeper literature. Tirzepatide has rapidly growing literature. For a study targeting publication in a general medical journal rather than a specialist pharmacology venue, alignment with established comparator literature matters.

The evolving landscape: what comes next#

The competitive landscape in this drug class is moving quickly and both compounds sit in a wider pipeline that affects the 2026 to 2028 research horizon.

Retatrutide, the Eli Lilly triple agonist that extends tirzepatide's dual agonism with glucagon receptor activity, is in Phase 3 development with expected first approval in 2026 or 2027. Retatrutide Phase 2 data showed mean weight reductions of approximately 24 percent at 48 weeks on the highest dose, exceeding tirzepatide's SURMOUNT numbers at similar timepoints. Once retatrutide is approved, the three-way comparison between retatrutide, tirzepatide, and semaglutide will be the defining set of choices in the class. The retatrutide research guide covers this compound in more depth.

Orforglipron, an Eli Lilly oral small-molecule GLP-1 receptor agonist, is in late-stage development. It produces weight loss comparable to injectable semaglutide at appropriate doses and could meaningfully change the oral alternative landscape for both compounds.

Amycretin, a Novo Nordisk combined GLP-1 and amylin agonist in a single molecule, is in earlier-stage development. Phase 1 data suggest weight-loss signals competitive with tirzepatide. If Phase 3 data confirm the signal, amycretin becomes the first mono-molecule compound to combine GLP-1 and amylin, changing the CagriSema landscape entirely.

Survodutide, a Boehringer Ingelheim GLP-1 and glucagon dual agonist (not tirzepatide's GIP plus GLP-1 dual but a different dual coverage), is in Phase 3 development with distinct mechanism-of-action properties that make it an interesting comparator for metabolic and liver-disease research.

The 2027 and 2028 research landscape will include at least four or five novel compounds with different receptor coverage patterns. For Canadian researchers starting a study today, choosing between semaglutide and tirzepatide is the 2026 question. Choosing between tirzepatide, retatrutide, orforglipron, survodutide, and amycretin will be the 2027 question. Study designs that can accommodate a new comparator arm as it becomes available tend to age better than studies locked into a single compound.